Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0348)
| Name |
1,6-O,O-diacetylbritannilactone
|
||||
|---|---|---|---|---|---|
| Synonyms |
1,6-O,O-diacetylbritannilactone; CHEMBL480459; [(4S)-4-[(3aR,4R,7aR)-4-acetyloxy-6-methyl-3-methylidene-2-oxo-3a,4,7,7a-tetrahydro-1-benzofuran-5-yl]pentyl] acetate
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C19H26O6
|
||||
| IUPAC Name |
[(4S)-4-[(3aR,4R,7aR)-4-acetyloxy-6-methyl-3-methylidene-2-oxo-3a,4,7,7a-tetrahydro-1-benzofuran-5-yl]pentyl] acetate
|
||||
| Canonical SMILES |
CC1=C(C(C2C(C1)OC(=O)C2=C)OC(=O)C)C(C)CCCOC(=O)C
|
||||
| InChI |
InChI=1S/C19H26O6/c1-10(7-6-8-23-13(4)20)16-11(2)9-15-17(12(3)19(22)25-15)18(16)24-14(5)21/h10,15,17-18H,3,6-9H2,1-2,4-5H3/t10-,15+,17+,18-/m0/s1
|
||||
| InChIKey |
MVCCWTMPDBIKCJ-IMKJFWDFSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Responsed Disease | Alzheimer disease | ICD-11: 8A20 | |||
| Pathway Response | Glutathione metabolism | hsa00480 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | BV-2 cells | Normal | Mus musculus | CVCL_0182 | |
| PC12 cells | Adrenal gland pheochromocytoma | Rattus norvegicus | CVCL_0481 | ||
| In Vivo Model |
OABL (20 mg/kg per day) dissolved in water with 10% ethanol and 10% Tween 80 was administrated to 6-month-old WT and 5xFAD mice for 3 weeks. WT+OABL and 5xFAD+OABL groups were treated by an intraperitoneal (i.p.) injection of OABL as the above-mentioned. OABL were dissolved in 10% ethanol, 10% Tween 80 and distilled water (according to 0.1% w/vol), and this solution of 10% ethanol, 10% Tween 80, and 80% distilled water was used as the vehicle. Mice from WT+Vehicle group and 5xFAD+Vehicle group were injected with the vehicle. Additional animal tests were conducted afteri.p.injection.
Click to Show/Hide
|
||||
| Response regulation | 1,6-O,O-diacetylbritannilactone (OABL) also significantly reduced the accumulation of amyloid plaques, the A expression, the phosphorylation of Tau protein, and the expression of BACE1 in Alzheimer's disease mice brain. OABL attenuated the overactivation of microglia and astrocytes by suppressing the expressions of inflammatory cytokines, and increased glutathione (GSH) and reduced malondialdehyde (MDA) and super oxide dismutase (SOD) levels in the 5xFAD mice brain. | ||||